Curvebeam Ai Limited

CVB.ASX

Health Care

Development, manufacture and sale of a range of specialised medical imaging scanners and software aids

Market Data

Price

$0.052

+0.1%
Market Cap

$23.4M

P/E Ratio

-100000.0x

EPS

$-0.039

Div. Yield

0.00%

52-Week Change

-0.5%

Latest Earnings

Appendix 4D - Interim Financial Report - Dec 2025 Half Year

27 February 2026

Revenue
$4.96
+1.1% YoY
NPAT
-$9.84
+6.4% YoY
EPS
$-0.02

CurveBeam AI Limited (ASX: CVB) reported HY FY2026 revenue of $4.96M, essentially flat (+1%) versus the prior corresponding period, while its net loss narrowed 6% to $9.84M from $10.52M. The improvement was driven by lower headcount costs following a November 2024 restructure and additional US payroll tax credits, partially offset by higher servicing costs and professional fees related to a new China distribution and licensing deal with WeiYing. The auditor's review includes a going concern paragraph, and with cash of $4.0M at 31 December 2025, liquidity remains a key risk — though a post-period $4M milestone payment from WeiYing provides near-term relief. Key points: Net loss narrowed by $0.68M (6%) to $9.84M, reflecting cost discipline after the November 2024 restructure reduced headcount expenses by $1.11M.; Revenue held steady at $4.96M (+1%), demonstrating resilience in the core WBCT equipment and AI SaaS business.; Completed a $6.5M placement in October 2025 at $0.09/share, providing near-term operating runway.

Recent Announcements

27 Feb 2026 Actual Results Neutral

Appendix 4D - Interim Financial Report - Dec 2025 Half Year

CurveBeam AI Limited (ASX: CVB) reported HY FY2026 revenue of $4.96M, essentially flat (+1%) versus the prior corresponding period, while its net loss narrowed 6% to $9.84M from $10.52M. The improvement was driven by lower headcount costs following a November 2024 restructure and additional US payroll tax credits, partially offset by higher servicing costs and professional fees related to a new China distribution and licensing deal with WeiYing. The auditor's review includes a going concern paragraph, and with cash of $4.0M at 31 December 2025, liquidity remains a key risk — though a post-period $4M milestone payment from WeiYing provides near-term relief. Key points: Net loss narrowed by $0.68M (6%) to $9.84M, reflecting cost discipline after the November 2024 restructure reduced headcount expenses by $1.11M.; Revenue held steady at $4.96M (+1%), demonstrating resilience in the core WBCT equipment and AI SaaS business.; Completed a $6.5M placement in October 2025 at $0.09/share, providing near-term operating runway.

Get real-time alerts for CVB

Receive AI-powered earnings summaries and instant notifications when Curvebeam Ai Limited releases results.

Register Free